Experimental Hematology
Volume 38, Issue 8 , Pages 685-695 , August 2010

A potential activity of valproic acid in the stimulation of interleukin-3−mediated megakaryopoiesis and erythropoiesis

  • Bing Liu

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Kohshi Ohishi

      Affiliations

    • Blood Transfusion Service, Mie University Hospital, Mie, Japan
    • Corresponding Author InformationOffprint requests to: Kohshi Ohishi, M.D., Ph.D, Blood Transfusion Service, Mie University Hospital, 2-174 Edobashi, Tsu, Mie 514-8507, Japan
    • ,
  • Kentaro Yamamura

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Kei Suzuki

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Fumihiko Monma

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Kazuko Ino

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Masahiro Masuya

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
    • ,
  • Takao Sekine

      Affiliations

    • Matsusaka Chuo General Hospital, Mie, Japan
    • ,
  • Yuji Heike

      Affiliations

    • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    • ,
  • Yoichi Takaue

      Affiliations

    • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    • ,
  • Naoyuki Katayama

      Affiliations

    • Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan

Received 12 December 2009 ,Revised 28 February 2010 ,Accepted 25 March 2010.

References 

  1. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–681
  2. Delcuve GP, Rastegar M, Davie JR. Epigenetic control. J Cell Physiol. 2009;219:243–250
  3. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009;280:192–200
  4. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005;96:293–304
  5. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007;17:195–211
  6. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005;23:635–642
  7. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther. 2008;7:740–748
  8. Altucci L, Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer. 2009;45:1137–1145
  9. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–6978
  10. Plass C, Oakes C, Blum W, Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol. 2008;35:378–387
  11. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25
  12. Bug G, Gul H, Schwarz K, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005;65:2537–2541
  13. De Felice L, Tatarelli C, Mascolo MG, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005;65:1505–1513
  14. Mahlknecht U, Schonbein C. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica. 2008;93:443–446
  15. Seet LF, Teng E, Lai YS, et al. Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur J Haematol. 2009;82:124–132
  16. Young JC, Wu S, Hansteen G, et al. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. Cytotherapy. 2004;6:328–336
  17. Yamamura K, Ohishi K, Katayama N, et al. Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis. Br J Haematol. 2006;135:242–253
  18. Goldfarb AN. Transcriptional control of megakaryocyte development. Oncogene. 2007;26:6795–6802
  19. Iwasaki H, Mizuno S, Wells RA, Cantor AB, Watanabe S, Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity. 2003;19:451–462
  20. Klimchenko O, Mori M, Distefano A, et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell- derived primitive hematopoiesis. Blood. 2009;114:1506–1517
  21. Wickrema A, Crispino JD. Erythroid and megakaryocytic transformation. Oncogene. 2007;26:6803–6815
  22. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34:206–222
  23. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951
  24. Yamamura K, Ohishi K, Katayama N, et al. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors. Cancer Sci. 2007;98:1597–1603
  25. Mouthon MA, Freund M, Titeux M, et al. Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. Blood. 1994;84:1085–1097
  26. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood. 1997;89:1471–1482
  27. Guthridge MA, Stomski FC, Thomas D, et al. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells. 1998;16:301–313
  28. Nakahata T, Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma. 1994;13:401–409
  29. Scicchitano MS, McFarland DC, Tierney LA, Narayanan PK, Schwartz LW. In vitro expansion of human cord blood CD36+ erythroid progenitors: temporal changes in gene and protein expression. Exp Hematol. 2003;31:760–769
  30. Yang M, Li K, Ng MH, et al. Thrombospondin-1 inhibits in vitro megakaryocytopoiesis via CD36. Thromb Res. 2003;109:47–54
  31. Berthier R, Valiron O, Schweitzer A, Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells. 1993;11:120–129
  32. Halle P, Rouzier C, Kanold J, et al. Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells. Ann Hematol. 2000;79:13–19
  33. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005;16:137–147
  34. Shimizu R, Yamamoto M. Gene expression regulation and domain function of hematopoietic GATA factors. Semin Cell Dev Biol. 2005;16:129–136
  35. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBP Differentiation Pathway in Human Cancer. J Clin Oncol. 2009;27:619–628
  36. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62–65
  37. Fujieda A, Katayama N, Ohishi K, et al. A putative role for histone deacetylase in the differentiation of human erythroid cells. Int J Oncol. 2005;27:743–748
  38. Nand S, Sosman J, Godwin JE, Fisher RI. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood. 1994;83:357–360
  39. Nimer SD, Paquette RL, Ireland P, Resta D, Young D, Golde DW. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 1994;22:875–880
  40. Rose C, Wattel E, Bastion Y, et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia. 1994;8:1458–1462
  41. Mangi MH, Newland AC. Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther. 1999;5:87–95
  42. Marsh JC, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol. 2007;44:138–147
  43. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607–3613
  44. Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009;115:706–715
  45. Ganser A, Ottmann OG, Hoelzer D. Interleukin-3 in the treatment of myelodysplastic syndromes. Int J Clin Lab Res. 1992;22:125–128
  46. Hopfer O, Komor M, Koehler IS, et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res. 2009;33:434–442
  47. Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer. 2007;110:943–954
  48. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;6:1268–1272
  49. Kanda J, Chonabayashi K, Watanabe M, Arima N, Tsudo M. Successful treatment with cyclosporine of sodium valproate-induced pure red cell aplasia. Rinsho Ketsueki. 2005;46:1114–1117
  50. Bottom KS, Adams DM, Mann KP, Ware RE. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol. 1997;19:73–76

PII: S0301-472X(10)00134-7

doi: 10.1016/j.exphem.2010.03.019

Experimental Hematology
Volume 38, Issue 8 , Pages 685-695 , August 2010

Article Tools

* Image Usage & Resolution